These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38419787)

  • 41. Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria.
    Verma S; Kosmopoulos A; Bhatt DL; Fitchett D; Ofstad AP; Wanner C; Mattheus M; Zinman B; Lawler PR; Leiter LA
    Am J Prev Cardiol; 2023 Sep; 15():100510. PubMed ID: 37384110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
    Ceriello A; Ofstad AP; Zwiener I; Kaspers S; George J; Nicolucci A
    Cardiovasc Diabetol; 2020 Oct; 19(1):176. PubMed ID: 33050931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors.
    Fernández-Fernandez B; Sarafidis P; Soler MJ; Ortiz A
    Clin Kidney J; 2023 Aug; 16(8):1187-1198. PubMed ID: 37529652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
    Böhm M; Fitchett D; Ofstad AP; Brueckmann M; Kaspers S; George JT; Zwiener I; Zinman B; Wanner C; Marx N; Mancia G; Anker SD; Mahfoud F
    J Hypertens; 2020 Sep; 38(9):1829-1840. PubMed ID: 32618884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
    Inzucchi SE; Zinman B; Fitchett D; Wanner C; Ferrannini E; Schumacher M; Schmoor C; Ohneberg K; Johansen OE; George JT; Hantel S; Bluhmki E; Lachin JM
    Diabetes Care; 2018 Feb; 41(2):356-363. PubMed ID: 29203583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
    Packer M; Anker SD; Butler J; Filippatos G; Pocock SJ; Carson P; Januzzi J; Verma S; Tsutsui H; Brueckmann M; Jamal W; Kimura K; Schnee J; Zeller C; Cotton D; Bocchi E; Böhm M; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Janssens S; Zhang J; Gonzalez Juanatey JR; Kaul S; Brunner-La Rocca HP; Merkely B; Nicholls SJ; Perrone S; Pina I; Ponikowski P; Sattar N; Senni M; Seronde MF; Spinar J; Squire I; Taddei S; Wanner C; Zannad F;
    N Engl J Med; 2020 Oct; 383(15):1413-1424. PubMed ID: 32865377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
    Kansal A; Reifsnider OS; Proskorovsky I; Zheng Y; Pfarr E; George JT; Kandaswamy P; Ruffolo A
    Diabet Med; 2019 Nov; 36(11):1494-1502. PubMed ID: 31295358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
    Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ
    Am J Kidney Dis; 2022 Feb; 79(2):244-256.e1. PubMed ID: 34029680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.
    Mozawa K; Kubota Y; Hoshika Y; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Maruyama M; Tanabe J; Shimizu W
    ESC Heart Fail; 2021 Oct; 8(5):4161-4173. PubMed ID: 34235875
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.
    Krämer BK; Hauske SJ; Chilton R; Mann JFE; Gullestad L; Fitchett D; Mattheus M; Steubl D; Wanner C
    J Diabetes Complications; 2023 Sep; 37(9):108588. PubMed ID: 37633072
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
    Zinman B; Inzucchi SE; Lachin JM; Wanner C; Fitchett D; Kohler S; Mattheus M; Woerle HJ; Broedl UC; Johansen OE; Albers GW; Diener HC;
    Stroke; 2017 May; 48(5):1218-1225. PubMed ID: 28386035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
    Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
    Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice.
    Fitchett DH
    Eur Endocrinol; 2018 Sep; 14(2):40-49. PubMed ID: 30349593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filippatos G; Pocock SJ; Brueckmann M; Steubl D; Schueler E; Anker SD; Packer M
    JAMA Cardiol; 2022 Nov; 7(11):1148-1159. PubMed ID: 36129693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
    Pratley RE; Cannon CP; Cherney DZI; Cosentino F; McGuire DK; Essex MN; Lawrence D; Jones PLS; Liu J; Adamsons I; Dagogo-Jack S
    Lancet Healthy Longev; 2023 Apr; 4(4):e143-e154. PubMed ID: 37003273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical trial designs to assess treatment effects on glomerular filtration rate decline.
    Heerspink HJL; Little DJ; Frison L; Gasparyan SB; Wanner C; Jongs N; Postmus D
    Kidney Int; 2024 Oct; 106(4):723-735. PubMed ID: 38969296
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
    Mayne KJ; Sardell RJ; Staplin N; Judge PK; Zhu D; Sammons E; Cherney DZ; Cheung AK; Maggioni AP; Nangaku M; Rossello X; Tuttle KR; Ihara K; Iwata T; Wanner C; Emberson J; Preiss D; Landray MJ; Baigent FMedSci C; Haynes R; Herrington WG;
    Clin J Am Soc Nephrol; 2024 Jul; 19(9):1119-29. PubMed ID: 38949880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.